David A. Flockhart

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

Zeruesenay Desta, Vered Stearns, Brent B. Ward et al. · JNCI Journal of the National Cancer Institute · 2005 · 942 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Matthew P. Goetz, James M. Rae, Vera J. Suman et al. · Journal of Clinical Oncology · 2005 · 786 citations · Full text

Medicine, Oncology, Pharmacology +16

Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

Zeruesenay Desta, Bryan A. Ward, Nadia Soukhova et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 645 citations

Medicine, Biochemistry, Pharmacology +17

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Bryan P. Schneider, Milan Radovich, George W. Sledge et al. · Journal of Clinical Oncology · 2008 · 608 citations · Full text

Medicine, Oncology, Pharmacology +17

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

Bryan A. Ward, J. Christopher Gorski, David R. Jones et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 594 citations

Medicine, Pharmacokinetics, Pharmacology +17